Indication
EGFR-TKI Resistant Mutation
3 clinical trials
3 products
Clinical trial
A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Product
BDTX-1535Clinical trial
A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2026-08-27
Product
NintedanibClinical trial
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance on Third-generation EGFR TKI： a Single-arm Phase II TrialStatus: Recruiting, Estimated PCD: 2025-12-15
Product
Osimertinib + Dalpiciclib